"And things seems to be moving in slow motion in US as well. I am not satisfied" seems to be a bit over dramatic. Remember they had only 7 weeks of US sales in this quarter. I am actually kind of impressed with the number.
$2.4 million in sales. At $8800, appx 272 patients treated (assume only 1 eye at a time). Drug shipped Feb 23 so a total of 36 days. That's about 8 patients treated a day. With no acceleration of scripts (staying flat), annual sales of $24 million. At a market cap of $198 million, that's 8x annual sales. Thoughts?
Not me. I think its just the uncertainty in anticipation of the earnings release. The run up today suggests positive news. We will know tomorrow!
Sentiment: Strong Buy
News is not bad, we really need 4 qtrs results for a Co. this size and a drug/device of this type to really show what the sales would be. No J Code and reimbursement issues continue but will end shortly, sales should pick up soon after.
No action is warranted at the moment, if the sellers beat this down the only action justified would be to load up. See you next Q.
I think their sales were weak for Q1 and their data on a significant improvement for this quarter were weak as well. In addition institutions that have participated in the conferences they've held are not buying the story.
Dan's optimism is great but they need to show that the docs are actually going to adopt this and that ALIM is not another money losing, 20 million in sales, little niche pharma.
Personally I'd like to see 10 mil in sales this quarter at a minimum. That's only 1200 or so units or 400 a month. Of the 1000 retina centers they are in contact with you could assume 60% of them do nothing and you would only need to sell one unit a month to the other 400 to hit 10 mil in sales.
It's now been almost 9 months since approval and they have a more open label than they expected. Time for Dan to deliver on years of promises!
Yes and yes. That's why to me they should be able to show us at least 400 units a month this quarter. 1/3 of that could come from Europe that leaves only 250 or so units a month in the US. If they can't do something near that I'm not sure how they will convince the institutional world to invest in the company. What large investors want to know is that alim has a clear path to profitability and no further need to raise cash. Absent that you will see continued lack of support like we are seeing now.
I think practices in many areas are waiting for the payment risk to pass. After Jan 1 there will be a dedicated J code to bill for getting paid in a timely manner. It can take up to 5 months to get paid and at $8800 that can affect cash flow.
PTX has been abysmal. You think it's finally a buy on weakness. Alim is a one trick pony, this pony is taking off. There is NOTHING else like this product for people with diabetes. I have seen what happens to the eyes and it's awful. I like this company. It will take time to implement, but the stock wont stay down for long.
Sentiment: Strong Buy
Those were my thoughts. I figured it was the best time to buy since it was at its 52wk low. I got in at $3.98. My dd makes me believe that this stock will see brighter days later this year.
What was with the Volume yesterday.. stock tanked by 6% in a single block of over 150k .. Some Index fund getting margin call on energy stocks and selling this to cover ?
nope but a bit disappointing. They been in the european marked for some time now but we se no pace there at all. And things seems to be moving in slow motion in US as well. I am not satisfied
Isn't thissthe Alimera board? Lame.
It shouldn't be a problem for a small co like alim to ramp up in this market because there are only 1000 retina centers they are focused on and they have 32 reps to cover them. It's not like they are calling on general practitioners and need 300-400 reps. The bigger issue is the perception by the docs as to whether or not it is an appropriate therapy for some portion of their patient base.
What would change the trajectory of stock price would be a quarter of sales that indicates progress on physician acceptance.